Skip to main content

Table 1 Serologic and global assessment parameters in patients with adult-onset Still's disease receiving 5 mg/kg infliximab

From: Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

  Baseline (mean) 8 weeks (mean)
C-reactive protein (mg/dL) 65 5
Erythrocyte sedimentation rate (mm/h) 53 16
Serum ferritin (mg/dL) 2952 58
Tender joint count 15 2.7
Swollen joint count 9 1.8